Ogeda announces fezolinetant as INN and issuance of US patent for ESN364

Gosselies, Belgium: 20 December 2016 - Ogeda, a clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting G-protein coupled receptors (GPCRs), announces today that the World Health Organization (WHO) has recommended fezolinetant as the International Nonproprietary Name (INN) for Ogeda's lead drug candidate ESN364.
Fezolinetant, Ogeda's orally-available and proprietary NK3 antagonist, is currently being evaluated in several double-blind, placebo controlled Phase II clinical trials for the treatment of multiple women's health disorders including menopausal hot flashes and polycystic ovary syndrome (PCOS).

Ogeda further announces the issuance of Patent No. US 9,422,299 entitled Substituted [1,2,4] Triazolo [4,3-A] Pyrazines as Selective NK3 Receptor Antagonists. The patent covers fezolinetant and closely related compounds as therapeutics in a broad range of diseases and disorders.

More info on Ogeda's website.


Next > Indigo announces successful Series A financing round

Previous > Confo Therapeutics to appoint John Berriman as Chairman of the Board